Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 51

1.

Clinical outcomes of polyvalent immunoglobulin use in solid organ transplant recipients: a systematic review and meta-analysis Part I: Kidney Transplant.

Bourassa-Blanchette S, Knoll GA, Hutton B, Fergusson N, Bennett A, Tay J, Cameron DW, Cowan J.

Clin Transplant. 2019 Apr 2:e13560. doi: 10.1111/ctr.13560. [Epub ahead of print]

PMID:
30938866
2.

Bortezomib Maintenance for the Treatment of Monoclonal Gammopathy of Renal Significance.

Lee H, Duggan P, Neri P, Tay J, Jimenez-Zepeda VH.

Mediterr J Hematol Infect Dis. 2019 Jan 1;11(1):e2019007. doi: 10.4084/MJHID.2019.007. eCollection 2019.

3.

Health related quality of life for multiple myeloma patients according to treatment strategy after autologous stem cell transplant: a cross-sectional study using EORTC, EQ-5D and MY-20 scales.

Tay J, Vij R, Norkin M, Buadi F, Kindwall-Keller TL, Roberts JS, White DJ, Wood RP, Blanthorn-Hazell SE, Rossi AC, Dhanasiri S, Zafar F, Newhouse K, McCurdy AR.

Leuk Lymphoma. 2019 May;60(5):1275-1282. doi: 10.1080/10428194.2018.1523399. Epub 2018 Oct 31.

PMID:
30380358
4.

Effectiveness of immunoglobulin prophylaxis in reducing clinical complications of hematopoietic stem cell transplantation: a systematic review and meta-analysis.

Ahn H, Tay J, Shea B, Hutton B, Shorr R, Knoll GA, Cameron DW, Cowan J.

Transfusion. 2018 Oct;58(10):2437-2452. doi: 10.1111/trf.14656. Epub 2018 May 16.

PMID:
29770447
5.

Long-term graft function following autologous hematopoietic cell transplantation and the impact of preemptive plerixafor in predicted poor mobilizers.

Visram A, Bredeson C, Allan D, Sabloff M, Huebsch L, Tay J, Kekre N, McDiarmid S, Mallick R, Tinmouth A, Martin L, Hamelin L, Maze D.

Blood Cancer J. 2018 Jan 29;8(1):14. doi: 10.1038/s41408-018-0050-2. No abstract available.

6.

Immunoparesis and polyclonal immunoglobulin recovery after auto-SCT for patients with multiple myeloma treated at a single institution.

Jimenez-Zepeda VH, Duggan P, Neri P, Chaudhry A, Tay J, Bahlis N.

Leuk Lymphoma. 2018 Aug;59(8):1920-1926. doi: 10.1080/10428194.2017.1403026. Epub 2017 Nov 21.

PMID:
29160734
7.

Early Relapse for Multiple Myeloma Patients Undergoing Single Autologous Stem Cell Therapy: A Single-center Experience.

Lee H, Duggan P, Chaudhry A, Neri P, Tay J, Rashid-Kolvear F, Bahlis NJ, Jimenez-Zepeda VH.

Clin Lymphoma Myeloma Leuk. 2018 Jan;18(1):e69-e75. doi: 10.1016/j.clml.2017.10.009. Epub 2017 Nov 1.

PMID:
29158114
8.

A national survey of screening and management of hypogammaglobulinemia in Canadian transplantation centers.

Bourassa-Blanchette S, Knoll G, Tay J, Bredeson C, Cameron DW, Cowan J.

Transpl Infect Dis. 2017 Aug;19(4). doi: 10.1111/tid.12706. Epub 2017 May 24.

PMID:
28423227
9.

Bortezomib-containing regimens (BCR) for the treatment of non-transplant eligible multiple myeloma.

Jimenez-Zepeda VH, Duggan P, Neri P, Tay J, Bahlis NJ.

Ann Hematol. 2017 Mar;96(3):431-439. doi: 10.1007/s00277-016-2901-x. Epub 2017 Jan 10.

PMID:
28074255
10.

Balancing give and take between patients and their spousal caregivers in hematopoietic stem cell transplantation.

Beattie S, Lebel S, Petricone-Westwood D, Wilson KG, Harris C, Devins G, Huebsch L, Tay J.

Psychooncology. 2017 Dec;26(12):2224-2231. doi: 10.1002/pon.4340. Epub 2017 Feb 2.

PMID:
27943606
11.

Zoster prophylaxis after allogeneic hematopoietic cell transplantation using acyclovir/valacyclovir followed by vaccination.

Jamani K, MacDonald J, Lavoie M, Williamson TS, Brown CB, Chaudhry A, Jimenez-Zepeda VH, Duggan P, Tay J, Stewart D, Daly A, Storek J.

Blood Adv. 2016 Nov 30;1(2):152-159. doi: 10.1182/bloodadvances.2016000836. eCollection 2016 Dec 13.

12.

Rationale and design of platelet transfusions in haematopoietic stem cell transplantation: the PATH pilot study.

Tay J, Allan D, Beattie S, Bredeson C, Fergusson D, Maze D, Sabloff M, Thavorn K, Tinmouth A.

BMJ Open. 2016 Oct 24;6(10):e013483. doi: 10.1136/bmjopen-2016-013483.

13.

Post-Transplant Outcomes in High-Risk Compared with Non-High-Risk Multiple Myeloma: A CIBMTR Analysis.

Scott EC, Hari P, Sharma M, Le-Rademacher J, Huang J, Vogl D, Abidi M, Beitinjaneh A, Fung H, Ganguly S, Hildebrandt G, Holmberg L, Kalaycio M, Kumar S, Kyle R, Lazarus H, Lee C, Maziarz RT, Meehan K, Mikhael J, Nishihori T, Ramanathan M, Usmani S, Tay J, Vesole D, Wirk B, Yared J, Savani BN, Gasparetto C, Krishnan A, Mark T, Nieto Y, D'Souza A.

Biol Blood Marrow Transplant. 2016 Oct;22(10):1893-1899. doi: 10.1016/j.bbmt.2016.07.007. Epub 2016 Aug 2.

14.

Optimal transfusion practices after allogeneic hematopoietic cell transplantation: a systematic scoping review of evidence from randomized controlled trials.

Christou G, Iyengar A, Shorr R, Tinmouth A, Saidenberg E, Maze D, Tay J, Bredeson C, Allan DS.

Transfusion. 2016 Oct;56(10):2607-2614. doi: 10.1111/trf.13738. Epub 2016 Jul 27. Review.

PMID:
27465524
15.

Revised International Staging System Applied to Real World Multiple Myeloma Patients.

Jimenez-Zepeda VH, Duggan P, Neri P, Rashid-Kolvear F, Tay J, Bahlis NJ.

Clin Lymphoma Myeloma Leuk. 2016 Sep;16(9):511-518. doi: 10.1016/j.clml.2016.06.001. Epub 2016 Jun 8.

PMID:
27425179
16.

Acquired Factor XIII Inhibitor in Hospitalized and Perioperative Patients: A Systematic Review of Case Reports and Case Series.

Tone KJ, James TE, Fergusson DA, Tinmouth A, Tay J, Avey MT, Kilty S, Lalu MM.

Transfus Med Rev. 2016 Jul;30(3):123-31. doi: 10.1016/j.tmrv.2016.04.001. Epub 2016 Apr 22. Review.

PMID:
27167905
17.

Myasthenia Gravis Treated With Autologous Hematopoietic Stem Cell Transplantation.

Bryant A, Atkins H, Pringle CE, Allan D, Anstee G, Bence-Bruckler I, Hamelin L, Hodgins M, Hopkins H, Huebsch L, McDiarmid S, Sabloff M, Sheppard D, Tay J, Bredeson C.

JAMA Neurol. 2016 Jun 1;73(6):652-8. doi: 10.1001/jamaneurol.2016.0113.

PMID:
27043206
18.

Heterogeneity of chronic graft-versus-host disease biomarkers: association with CXCL10 and CXCR3+ NK cells.

Kariminia A, Holtan SG, Ivison S, Rozmus J, Hebert MJ, Martin PJ, Lee SJ, Wolff D, Subrt P, Abdossamadi S, Sung S, Storek J, Levings M, Aljurf M, Arora M, Cutler C, Gallagher G, Kuruvilla J, Lipton J, Nevill TJ, Newell LF, Panzarella T, Pidala J, Popradi G, Szwajcer D, Tay J, Toze CL, Walker I, Couban S, Storer BE, Schultz KR.

Blood. 2016 Jun 16;127(24):3082-91. doi: 10.1182/blood-2015-09-668251. Epub 2016 Mar 28.

19.

Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study.

Dimopoulos MA, Moreau P, Palumbo A, Joshua D, Pour L, Hájek R, Facon T, Ludwig H, Oriol A, Goldschmidt H, Rosiñol L, Straub J, Suvorov A, Araujo C, Rimashevskaya E, Pika T, Gaidano G, Weisel K, Goranova-Marinova V, Schwarer A, Minuk L, Masszi T, Karamanesht I, Offidani M, Hungria V, Spencer A, Orlowski RZ, Gillenwater HH, Mohamed N, Feng S, Chng WJ; ENDEAVOR Investigators.

Lancet Oncol. 2016 Jan;17(1):27-38. doi: 10.1016/S1470-2045(15)00464-7. Epub 2015 Dec 5.

20.

Improved Prediction of CD34+ Cell Yield before Peripheral Blood Hematopoietic Progenitor Cell Collection Using a Modified Target Value-Tailored Approach.

Sheppard D, Tay J, Palmer D, Xenocostas A, Doulaverakis C, Huebsch L, McDiarmid S, Tinmouth A, Mallick R, Martin L, Birch P, Hamelin L, Allan D, Bredeson C.

Biol Blood Marrow Transplant. 2016 Apr;22(4):763-767. doi: 10.1016/j.bbmt.2015.11.016. Epub 2015 Nov 28.

Supplemental Content

Loading ...
Support Center